Paul F. Lizzul - Sep 23, 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
Chief Medical Officer
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Stock symbol
ANAB
Transactions as of
Sep 23, 2024
Transactions value $
-$30,255
Form type
4
Date filed
9/24/2024, 04:18 PM
Previous filing
Sep 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $27.8K +1.5K +9.74% $18.50 16.9K Sep 23, 2024 Direct
transaction ANAB Common Stock Sale -$58K -1.5K -8.88% $38.67 15.4K Sep 23, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Common Options Exercise $0 -1.5K -1.73% $0.00 85K Sep 23, 2024 Common 1.5K $18.50 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2024.
F2 The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 31, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
F3 In addition to the remaining options to purchase 85,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 297,610 shares of common stock, which options vest according to their terms.